Razelle Kurzrock

Razelle Kurzrock

Hematology | Oncology

9200 W Wisconsin Ave
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 746 publications

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.

Journal: Hematology/oncology clinics of North America

Published: September 02, 2026

Worldwide Innovative Network Consortium: Building a Common Global Cancer Database.

Worldwide Innovative Network Consortium: Building a Common Global Cancer Database.

Journal: JCO global oncology

Published: August 13, 2026

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

Journal: Oncotarget

Published: July 21, 2026

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

Universal Germline Genetic Testing in a Precision Oncology and Rare Cancer Clinic: Implementation and Outcomes.

Universal Germline Genetic Testing in a Precision Oncology and Rare Cancer Clinic: Implementation and Outcomes.

Journal: JCO oncology advances

Published: July 09, 2026

Beyond one gene, one target: Next-generation precision oncology.

Beyond one gene, one target: Next-generation precision oncology.

Journal: Trends in cancer

Published: May 07, 2026

Navigating Complexity in the Precision Oncology Clinic: Pharmacists' Central Role in Drug Selection, Acquisition, and Dosing in a Real-World Clinic.

Navigating Complexity in the Precision Oncology Clinic: Pharmacists' Central Role in Drug Selection, Acquisition, and Dosing in a Real-World Clinic.

Journal: Journal of immunotherapy and precision oncology

Published: April 22, 2026

TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations.

TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment.

Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment.

Journal: JCO precision oncology

Published: April 03, 2026

TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations.

TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

Journal: Cancer research

Published: March 21, 2026

The case for tumour-agnostic reimbursement of dual immunotherapy.

The case for tumour-agnostic reimbursement of dual immunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 07, 2026

Showing 1-12 of 746

Last Updated: 09/26/2026